Aniket Malhotra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Aniket Malhotra has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Gray McPherson
Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, AL (AM, GEM, LL)
2 shared publications - Heather Lee
University of Alabama at Birmingham, AL, USA
2 shared publications - Larry R. Hearld
The University of Alabama at Birmingham, USA
2 shared publications - Lauren A. Walter
Department of Emergency Medicine University of Alabama at Birmingham Birmingham Alabama USA
2 shared publications - Li Li
Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, United States
2 shared publications - Rohit Chaparala
Department of Orthopaedic Surgery, University of Alabama at Birmingham, United States
2 shared publications
Latest Publications
- Open Access
- 17 November 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e109601
A Comprehensive Intervention to Enhance Treatment Engagement and Retention Following Nonfatal Opioid Overdose: Protocol for a Single-Arm Prospective Feasibility Study
Background: Substance use treatment engagement and retention after hospital discharge remain low among patients with nonfatal opioid overdose. It is critical to develop interventions targeting this population due to the persistent opioid overdose crisis. Objective: We conducted a single-arm prospective study, the first phase of a 2-phase study (R61/R33, funded by the National Institute on Drug Abuse; DA062351). The objective of the R61 phase was to evaluate the feasibility and acceptability of a 12-week bundled telehealth-enabled intervention aimed at improving treatment engagement and retention among patients with opioid use disorder and a recent nonfatal opioid overdose after hospital discharge. Methods: The R61 phase was a single-arm study with no control group. The 12-week comprehensive intervention comprised 4 components, including buprenorphine treatment, telehealth physician visits (weeks 1, 3, 5, 9, and 12 and as needed), telehealth peer service (daily during week 1, every other day during week 2, weekly during weeks 3-12, and as needed), and facilitated linkage to community resources and ongoing treatment. Adults aged 19 years or older with a diagnosis of opioid use disorder and a nonfatal opioid overdose within the previous 12 months were recruited before they were discharged from the University of Alabama at Birmingham Hospital. After enrollment, buprenorphine treatment was initiated or continued, and peer support specialists began engaging and coaching patients. Participants completed validated surveys at baseline and 1 and 3 months. Feasibility will be measured using enrollment and retention rates (benchmark of ≥70% at 3 months). Acceptability will be measured using patient satisfaction and credibility and expectancy scores. Mental health, craving, repeat overdose, and emergency department revisits and readmissions are secondary outcomes. Outcomes will be summarized descriptively. Results: The R61 study was funded by the National Institute on Drug Abuse from October 1, 2024, to August 30, 2026. All 30 anticipated participants were enrolled, and 24 completed the intervention. The last participant completed the intervention in April 2026. Data analysis is currently ongoing, and results from the current study are expected to be published in January 2027. Funding for the subsequent R33 phase was awarded in September 2026. Conclusions: This study evaluated the feasibility and acceptability of a bundled telehealth-enabled intervention for patients at high risk of repeat overdose and death, a patient population with low treatment uptake and retention after hospital discharge. The findings will inform the upcoming R33 phase, a randomized controlled trial aiming to demonstrate effectiveness in an estimated sample of 160 patients. International Registered Report Identifier (IRRID): DERR1-10.2196/109601
- 17 November 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e109601
Open AccessA Comprehensive Intervention to Enhance Treatment Engagement and Retention Following Nonfatal Opioid Overdose: Protocol for a Single-Arm Prospective Feasibility Study
Background: Substance use treatment engagement and retention after hospital discharge remain low among patients with nonfatal opioid overdose. It is critical to develop interventions targeting this population due to the persistent opioid overdose crisis. Objective: We conducted a single-arm prospective study, the first phase of a 2-phase study (R61/R33, funded by the National Institute on Drug Abuse; DA062351). The objective of the R61 phase was to evaluate the feasibility and acceptability of a 12-week bundled telehealth-enabled intervention aimed at improving treatment engagement and retention among patients with opioid use disorder and a recent nonfatal opioid overdose after hospital discharge. Methods: The R61 phase was a single-arm study with no control group. The 12-week comprehensive intervention comprised 4 components, including buprenorphine treatment, telehealth physician visits (weeks 1, 3, 5, 9, and 12 and as needed), telehealth peer service (daily during week 1, every other day during week 2, weekly during weeks 3-12, and as needed), and facilitated linkage to community resources and ongoing treatment. Adults aged 19 years or older with a diagnosis of opioid use disorder and a nonfatal opioid overdose within the previous 12 months were recruited before they were discharged from the University of Alabama at Birmingham Hospital. After enrollment, buprenorphine treatment was initiated or continued, and peer support specialists began engaging and coaching patients. Participants completed validated surveys at baseline and 1 and 3 months. Feasibility will be measured using enrollment and retention rates (benchmark of ≥70% at 3 months). Acceptability will be measured using patient satisfaction and credibility and expectancy scores. Mental health, craving, repeat overdose, and emergency department revisits and readmissions are secondary outcomes. Outcomes will be summarized descriptively. Results: The R61 study was funded by the National Institute on Drug Abuse from October 1, 2024, to August 30, 2026. All 30 anticipated participants were enrolled, and 24 completed the intervention. The last participant completed the intervention in April 2026. Data analysis is currently ongoing, and results from the current study are expected to be published in January 2027. Funding for the subsequent R33 phase was awarded in September 2026. Conclusions: This study evaluated the feasibility and acceptability of a bundled telehealth-enabled intervention for patients at high risk of repeat overdose and death, a patient population with low treatment uptake and retention after hospital discharge. The findings will inform the upcoming R33 phase, a randomized controlled trial aiming to demonstrate effectiveness in an estimated sample of 160 patients. International Registered Report Identifier (IRRID): DERR1-10.2196/109601
- Open Access
- 14 August 2026
- Published by JMIR Publications Inc. in JMIR Preprints
A Comprehensive Intervention to Enhance Treatment Engagement and Retention Following Nonfatal Opioid Overdose: Protocol for a Single-Arm Prospective Feasibility Study (Preprint)
BACKGROUND Substance use treatment engagement and retention after hospital discharge remain low among patients with nonfatal opioid overdose. It is critical to develop interventions targeting this population due to the persistent opioid overdose crisis. OBJECTIVE We conducted a single-arm prospective study, the first phase of a 2-phase study (R61/R33, funded by the National Institute on Drug Abuse; DA062351). The objective of the R61 phase was to evaluate the feasibility and acceptability of a 12-week bundled telehealth-enabled intervention aimed at improving treatment engagement and retention among patients with opioid use disorder and a recent nonfatal opioid overdose after hospital discharge. METHODS The R61 phase was a single-arm study with no control group. The 12-week comprehensive intervention comprised 4 components, including buprenorphine treatment, telehealth physician visits (weeks 1, 3, 5, 9, and 12 and as needed), telehealth peer service (daily during week 1, every other day during week 2, weekly during weeks 3-12, and as needed), and facilitated linkage to community resources and ongoing treatment. Adults aged 19 years or older with a diagnosis of opioid use disorder and a nonfatal opioid overdose within the previous 12 months were recruited before they were discharged from the University of Alabama at Birmingham Hospital. After enrollment, buprenorphine treatment was initiated or continued, and peer support specialists began engaging and coaching patients. Participants completed validated surveys at baseline and 1 and 3 months. Feasibility will be measured using enrollment and retention rates (benchmark of ≥70% at 3 months). Acceptability will be measured using patient satisfaction and credibility and expectancy scores. Mental health, craving, repeat overdose, and emergency department revisits and readmissions are secondary outcomes. Outcomes will be summarized descriptively. RESULTS The R61 study was funded by the National Institute on Drug Abuse from October 1, 2024, to August 30, 2026. All 30 anticipated participants were enrolled, and 24 completed the intervention. The last participant completed the intervention in April 2026. Data analysis is currently ongoing, and results from the current study are expected to be published in January 2027. Funding for the subsequent R33 phase was awarded in September 2026. CONCLUSIONS This study evaluated the feasibility and acceptability of a bundled telehealth-enabled intervention for patients at high risk of repeat overdose and death, a patient population with low treatment uptake and retention after hospital discharge. The findings will inform the upcoming R33 phase, a randomized controlled trial aiming to demonstrate effectiveness in an estimated sample of 160 patients. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/109601
- 14 August 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessA Comprehensive Intervention to Enhance Treatment Engagement and Retention Following Nonfatal Opioid Overdose: Protocol for a Single-Arm Prospective Feasibility Study (Preprint)
BACKGROUND Substance use treatment engagement and retention after hospital discharge remain low among patients with nonfatal opioid overdose. It is critical to develop interventions targeting this population due to the persistent opioid overdose crisis. OBJECTIVE We conducted a single-arm prospective study, the first phase of a 2-phase study (R61/R33, funded by the National Institute on Drug Abuse; DA062351). The objective of the R61 phase was to evaluate the feasibility and acceptability of a 12-week bundled telehealth-enabled intervention aimed at improving treatment engagement and retention among patients with opioid use disorder and a recent nonfatal opioid overdose after hospital discharge. METHODS The R61 phase was a single-arm study with no control group. The 12-week comprehensive intervention comprised 4 components, including buprenorphine treatment, telehealth physician visits (weeks 1, 3, 5, 9, and 12 and as needed), telehealth peer service (daily during week 1, every other day during week 2, weekly during weeks 3-12, and as needed), and facilitated linkage to community resources and ongoing treatment. Adults aged 19 years or older with a diagnosis of opioid use disorder and a nonfatal opioid overdose within the previous 12 months were recruited before they were discharged from the University of Alabama at Birmingham Hospital. After enrollment, buprenorphine treatment was initiated or continued, and peer support specialists began engaging and coaching patients. Participants completed validated surveys at baseline and 1 and 3 months. Feasibility will be measured using enrollment and retention rates (benchmark of ≥70% at 3 months). Acceptability will be measured using patient satisfaction and credibility and expectancy scores. Mental health, craving, repeat overdose, and emergency department revisits and readmissions are secondary outcomes. Outcomes will be summarized descriptively. RESULTS The R61 study was funded by the National Institute on Drug Abuse from October 1, 2024, to August 30, 2026. All 30 anticipated participants were enrolled, and 24 completed the intervention. The last participant completed the intervention in April 2026. Data analysis is currently ongoing, and results from the current study are expected to be published in January 2027. Funding for the subsequent R33 phase was awarded in September 2026. CONCLUSIONS This study evaluated the feasibility and acceptability of a bundled telehealth-enabled intervention for patients at high risk of repeat overdose and death, a patient population with low treatment uptake and retention after hospital discharge. The findings will inform the upcoming R33 phase, a randomized controlled trial aiming to demonstrate effectiveness in an estimated sample of 160 patients. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/109601
- 7 July 2026
- Published by Taylor & Francis in Journal of Addictive Diseases
- p. 1-11
Evidence-informed approaches to medication management for opioid use disorder in special populations: a narrative review
Opioid use disorder remains a critical public health challenge, marked by high prevalence, overdose deaths, and substantial societal burden. Despite the availability of effective medications for OUD (MOUD), treatment utilization remains suboptimal, particularly among special populations. Contributing factors include altered pharmacokinetics, complex comorbidities, heightened safety concerns, stigma, and limited clinician expertise. This review comprehensively summarizes the latest evidence and guidelines to inform approaches to medications for opioid use disorder in special populations, including individuals with hepatic, renal, or cardiovascular disease; HIV/AIDS; peripartum or breastfeeding status; concurrent alcohol or benzodiazepine use; perioperative care needs; and adolescence. Across these populations, MOUD are associated with reduced morbidity and mortality and should not be withheld solely due to medical comorbidity, pregnancy, concurrent substance use, or perioperative care needs. Methadone is consistently associated with the highest treatment retention but requires careful dosing and monitoring in patients with hepatic, renal, and cardiovascular disease and in those receiving interacting medications, including antiretroviral therapy. Buprenorphine demonstrates a favorable safety profile across medically complex populations and fewer clinically significant drug-drug interactions. Extended-release naltrexone may be appropriate for select patients who can maintain opioid abstinence prior to induction, though its use is constrained by initiation barriers and limited population-specific data. Persistent access gaps, particularly among adolescents, highlight the need for tailored implementation strategies and further research. Consequently, recognizing the distinct needs and barriers of special populations with OUD is essential, and tailoring care to these considerations can enhance treatment outcomes.
- 7 July 2026
- Published by Taylor & Francis in Journal of Addictive Diseases
- p. 1-11
Evidence-informed approaches to medication management for opioid use disorder in special populations: a narrative review
Opioid use disorder remains a critical public health challenge, marked by high prevalence, overdose deaths, and substantial societal burden. Despite the availability of effective medications for OUD (MOUD), treatment utilization remains suboptimal, particularly among special populations. Contributing factors include altered pharmacokinetics, complex comorbidities, heightened safety concerns, stigma, and limited clinician expertise. This review comprehensively summarizes the latest evidence and guidelines to inform approaches to medications for opioid use disorder in special populations, including individuals with hepatic, renal, or cardiovascular disease; HIV/AIDS; peripartum or breastfeeding status; concurrent alcohol or benzodiazepine use; perioperative care needs; and adolescence. Across these populations, MOUD are associated with reduced morbidity and mortality and should not be withheld solely due to medical comorbidity, pregnancy, concurrent substance use, or perioperative care needs. Methadone is consistently associated with the highest treatment retention but requires careful dosing and monitoring in patients with hepatic, renal, and cardiovascular disease and in those receiving interacting medications, including antiretroviral therapy. Buprenorphine demonstrates a favorable safety profile across medically complex populations and fewer clinically significant drug-drug interactions. Extended-release naltrexone may be appropriate for select patients who can maintain opioid abstinence prior to induction, though its use is constrained by initiation barriers and limited population-specific data. Persistent access gaps, particularly among adolescents, highlight the need for tailored implementation strategies and further research. Consequently, recognizing the distinct needs and barriers of special populations with OUD is essential, and tailoring care to these considerations can enhance treatment outcomes.
- 1 May 2025
- Published by American Psychological Association (APA) in Psychological Trauma: Theory, Research, Practice, and Policy
- Vol. 17 (4) , 857-865
Drug misuse, self-esteem, and intimate partner violence among low-income African American women.
Little attention has been paid to the association between drug misuse and intimate partner violence (IPV) in low-income African American women or factors that protect African American women with drug misuse from IPV exposure. To fill these gaps, this study examined if the drug misuse-IPV exposure link was moderated by self-esteem in the target population. Participants (n = 204; Mage = 36.8 years, SDage = 11.1), low-income African American women with a recent suicide attempt and IPV exposure, were recruited from a large, public health care system and completed measures assessing drug use, self-esteem, and IPV. Drug misuse correlated only with physical IPV (r = .16, p < .05). Self- and other-based self-esteem correlated with physical (r = -.25, p < .01 and r = -.34, p < .01, respectively) and nonphysical (r = -.33, p < .01 and r = -.41, p < .01, respectively) IPV. Moderation analyses revealed an interaction of drug use and other-based self-esteem on nonphysical IPV (B = -.26, SE = .06, p < .001); women with higher other-based self-esteem were more likely to be exposed to the negative effects of drug misuse on their reports of nonphysical IPV severity. There was no interaction of drug use and other-based self-esteem on physical IPV exposure or of self-based self-esteem on either type of IPV. Interventions that enhance African American women's perceptions of how they believe others view them may protect them against nonphysical IPV, but they also may require interventions to address drug misuse if present. (PsycInfo Database Record (c) 2025 APA, all rights reserved).
- 1 May 2025
- Published by American Psychological Association (APA) in Psychological Trauma: Theory, Research, Practice, and Policy
- Vol. 17 (4) , 857-865
Drug misuse, self-esteem, and intimate partner violence among low-income African American women.
Little attention has been paid to the association between drug misuse and intimate partner violence (IPV) in low-income African American women or factors that protect African American women with drug misuse from IPV exposure. To fill these gaps, this study examined if the drug misuse-IPV exposure link was moderated by self-esteem in the target population. Participants (n = 204; Mage = 36.8 years, SDage = 11.1), low-income African American women with a recent suicide attempt and IPV exposure, were recruited from a large, public health care system and completed measures assessing drug use, self-esteem, and IPV. Drug misuse correlated only with physical IPV (r = .16, p < .05). Self- and other-based self-esteem correlated with physical (r = -.25, p < .01 and r = -.34, p < .01, respectively) and nonphysical (r = -.33, p < .01 and r = -.41, p < .01, respectively) IPV. Moderation analyses revealed an interaction of drug use and other-based self-esteem on nonphysical IPV (B = -.26, SE = .06, p < .001); women with higher other-based self-esteem were more likely to be exposed to the negative effects of drug misuse on their reports of nonphysical IPV severity. There was no interaction of drug use and other-based self-esteem on physical IPV exposure or of self-based self-esteem on either type of IPV. Interventions that enhance African American women's perceptions of how they believe others view them may protect them against nonphysical IPV, but they also may require interventions to address drug misuse if present. (PsycInfo Database Record (c) 2025 APA, all rights reserved).
- 8 August 2023
- Published by Wiley in The American Journal on Addictions
- Vol. 32 (5) , 433-441
Medication treatment for alcohol use disorder in special populations
Background and Objectives: Alcohol use disorder (AUD) is a significant public health concern, with underutilized effective treatments, particularly in special populations. This article summarizes the current evidence and guidelines for treating AUD in special populations.Methods: This article is a literature review that synthesizes the latest research on AUD treatment for special populations. We screened 242 articles and included 57 in our final review.Results: There are four food and Drug Administration‐approved medications for AUD (MAUD): disulfiram, oral naltrexone, extended‐release injectable naltrexone (XR‐NTX), and acamprosate. Naltrexone and disulfiram have the potential to cause liver toxicity, and acamprosate should be avoided in patients with severe kidney disease. Psychosocial treatments should be considered first‐line for pregnant and nursing patients. Naltrexone is contraindicated in patients on opioids, as it may precipitate acute withdrawal. For patients experiencing homelessness, nonabstinent treatment goals may be more practical, and XR‐NTX should be considered to improve adherence. Limited evidence suggests medication can improve AUD treatment outcomes in adolescents and young adults. For patients with poor treatment response despite adequate medication adherence, switching to a different medication and augmentation with psychosocial treatments should be considered.Discussion and Conclusions: Understanding the unique considerations for special populations with AUD is crucial, and addressing their special needs may improve their treatment outcomes.Scientific Significance: Our study significantly contributes to the existing literature by summarizing crucial information for the treatment of AUD in special populations, highlighting distinct challenges, and emphasizing tailored approaches to improve overall health and well‐being.
- 8 August 2023
- Published by Wiley in The American Journal on Addictions
- Vol. 32 (5) , 433-441
Medication treatment for alcohol use disorder in special populations
Background and Objectives: Alcohol use disorder (AUD) is a significant public health concern, with underutilized effective treatments, particularly in special populations. This article summarizes the current evidence and guidelines for treating AUD in special populations.Methods: This article is a literature review that synthesizes the latest research on AUD treatment for special populations. We screened 242 articles and included 57 in our final review.Results: There are four food and Drug Administration‐approved medications for AUD (MAUD): disulfiram, oral naltrexone, extended‐release injectable naltrexone (XR‐NTX), and acamprosate. Naltrexone and disulfiram have the potential to cause liver toxicity, and acamprosate should be avoided in patients with severe kidney disease. Psychosocial treatments should be considered first‐line for pregnant and nursing patients. Naltrexone is contraindicated in patients on opioids, as it may precipitate acute withdrawal. For patients experiencing homelessness, nonabstinent treatment goals may be more practical, and XR‐NTX should be considered to improve adherence. Limited evidence suggests medication can improve AUD treatment outcomes in adolescents and young adults. For patients with poor treatment response despite adequate medication adherence, switching to a different medication and augmentation with psychosocial treatments should be considered.Discussion and Conclusions: Understanding the unique considerations for special populations with AUD is crucial, and addressing their special needs may improve their treatment outcomes.Scientific Significance: Our study significantly contributes to the existing literature by summarizing crucial information for the treatment of AUD in special populations, highlighting distinct challenges, and emphasizing tailored approaches to improve overall health and well‐being.